Loading patent…
AssigneesSanofi Pasteur Limited, SK Bioscience Co., Ltd.
InventorsKyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
Estimating the term…
Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
A monovalent pneumococcal conjugate composition comprising a serotype 9N conjugate, wherein the serotype 9N conjugate comprises a protein carrier conjugated to a capsular polysaccharide from Streptococcus pneumoniae serotype 9N, wherein the protein carrier is CRM197, wherein the capsular polysaccharide from serotype 9N is conjugated to CRM197 in a state where the capsular polysaccharide from serotype 9N is activated to have a degree of oxidation of 2-19 and a molecular weight of 200-700 kDa, and wherein the monovalent pneumococcal conjugate composition comprises less than 45% of a free capsular polysaccharide from serotype 9N based on the total amount of the capsular polysaccharide from serotype 9N.
Dependencies are inferred from the claim text.